Introduction
The prevalence of diabetes has reached epidemic proportions in most populations. Epidemiologic evidences suggest that unless effective preventive measures are implemented, the prevalence will continue to rise globally. 1 It is estimated that the number is expected to grow to 366 million by 2030, more than twice the number in 2000. 2 In a national survey in Iran, the prevalence of type 2 diabetes mellitus (T2DM) was reported to be 7.7% in people younger than 65 years. 3 Intensive glycemic control has a beneficial effect on diabetes-related complications. 4 Hemoglobin A1c (HbA1c) reflects the overall blood glucose control. [5] [6] [7] Landmark studies confirmed that postprandial hyperglycemia is an independent risk factor for vascular events. 8, 9 Dysglycemia in diabetes is not limited to sustained chronic hyperglycemia. Acute glycemic variability seems to activate oxidative stress and plays a major role in the pathogenesis of diabetic complications. 7, 10, 11 Self-monitoring of blood glucose (SMBG) enables physicians and patients to evaluate glycemic state and its variability. [12] [13] [14] It may also reduce the risk of asymptomatic hypoglycemia and/or hyperglycemia. [14] [15] [16] Conflicting evidence exists regarding the beneficial effect of SMBG in T2DM. [17] [18] [19] [20] [21] The purpose of this observational study was to investigate the effect of patient self-management behaviors on metabolic outcomes in a group of people with T2DM using a structured self-monitoring method.
Participants and Methods

Study Design
The Institute of Endocrinology and Metabolism (IEM) at Tehran University of Medical Sciences conducted this study to assess the merits of a structured testing-based tool (ACCU-CHEK 360° View) in adults with T2DM. 22 After exclusion of those with advanced chronic complications, pregnancy, and other concurrent illness, 30 people with T2DM were included in the study from January to June 2009. At baseline, all patients received education about the meter device as well as essential instructions in order to record the results in a data collection paper tool. This tool provides an adequate basis for seven-point SMBG for 3 consecutive days and includes three premeals, three postmeals, and bedtime blood glucose values during each day. There is enough space for patients to mark preceding portion size as small, medium, or large. Also, patients could put their comments about level of physical activity at determined points at the bottom of the paper.
Basic core education was provided to the subjects so that they could act upon the results by changing portion size of the meals and level of physical activity. In this phase, compliance of the subjects was evaluated and those with good compliance were enrolled in the study. Good compliance was defined as recording more than 85% of the dates correctly on the paper tool.
All patients were supplied with meters, strips, lancets, and lancing devices, plus the 360° View forms and were asked to record their blood glucose values, portion size, and level of physical activity at the end of each month on 3 consecutive days: S1 (days 28-30), S2 (days 58-60), and S3 (days 88-90). All subjects received a reminder call 1 day prior to S1, S2, and S3 and were asked to analyze test results in relation to portion size and level of physical activity, and act on the results according to the instructions they received at the time of enrollment. A double-check system was applied to all test results by downloading data from the meters using an infrared port. Medical treatment for all subjects remained unchanged during the study. The major cause of dropouts was change in treatment protocol. S1 and S3 glucose profiles were used for comparison.
HbA1c was measured twice in each patient, at inclusion and at the end of study, using ion exchange chromatography (Drew-DS5, Drew Scientific Co. Limited, Cumbria, England). Poor glycemic control was defined as HbA1c ≥8% at inclusion. Two groups were identified according to HbA1c: 15 patients with HbA1c less than 8% (group A) and 15 patients with HbA1c ≥8% (group B). Ethical approval was granted from the ethics board at IEM.
Statistical Analysis
All data are presented as mean ± standard deviation (SD). Significant differences in general characteristics were determined by Chi-square and Student's t-test. SPSS for Windows (Version 16; SPSS Inc., Chicago, IL) was used for data analyses and p values < .05 were considered statistically significant.
Results
Twenty-three patients (10 patients in group A and 13 patients in group B) completed the study. There were no significant differences in baseline characteristics, including age, duration of diabetes, and SMBG frequency. However, subjects in group B had a significantly higher baseline HbA1c (mean (SD) 6.57% (1.01) vs 9.72% (1.35); p value < .001) ( Table 1) . Each of the 23 patients included in the final analysis had four series of 72-84 readings of SMBG results recorded in ACCU-CHEK 360° View forms (a total of at least 1656 and at most 1921 SMBG readings in each of the four series).
Outcome Measures
HbA1c
The primary end point, HbA1c, improved during the 90-day period with a statistically significant decrease in group B [confidence interval (CI) 95%, 0.86-2.64%, p < .05), and in all cases (CI 95%, 0.32-1.64%, p < .05) ( Table 2) . As expected, there was no significant change in HbA1c values in group A. It was also noted that 53% of subjects in group B reached an HbA1c of less than 8% at the end of the study.
Mean Blood Glucose
Mean blood glucose (MBG) values significantly decreased in group B (CI 95%, 0.56-24.78 mg/dl, p < .05), and in all subjects (CI 95%, 1.61-19.73 mg/dl, p < .05). However, MBG did not show any significant difference in group A ( Table 3) . Table 3 shows an average decrease of 15.7 mg/dl in fasting blood sugar (FBS) levels in all subjects (95% CI, 0.66-30.84 mg/dl, p < .05). The decrease in mean FBS values of groups A and B were not statistically significant.
Fasting Blood Sugar
Mean Postprandial Blood Glucose
Also of note was the 19.3 mg/dl decrease in mean postprandial blood glucose levels (MPP) in group B (CI 95%, 5.51-33.20 mg/dl, p < .05), and the 11.3 mg/dl decrease in all subjects (CI 95%, 0.43-22.12 mg/dl, p < .05). However, there was no significant change in MPP in group A ( Table 3 ).
Discussion
The purpose of this study was to evaluate the effect of structured SMBG on self-management behavior and metabolic outcomes in people with T2DM. We found that this strategy improves HbA1c, FBS, MPP, and MBG in patients with poor glycemic control. Interestingly, this effect was independent of medical treatment and showed the importance of lifestyle changes.
Comparison of HbA1c Values between Groups of Inclusion and End of the Study
Guerci and colleagues 23 reported the effectiveness of SMBG on metabolic control in patients with T2DM in a multicenter controlled prospective trail. They showed SMBG is more beneficial in patients with higher HbA1c at baseline, a finding that is similar to ours. In this study, however, no standard counseling on diet and lifestyle was done for the patients.
In a study by Rutten and colleagues, 24 the beneficial effect of SMBG on weight and HbA1c was shown. Similar results were reported in a prospective randomized controlled multicenter study on glycemic control in patients with T2DM. 21 In this study, SMBG in combination with a structured canceling program improved mealrelated glucose levels.
In DINAMIC 1, 25 the value of SMBG on reduction of HbA1c was shown in a randomized parallel study in patients with T2DM who were on oral antidiabetic therapy. In the Auto-Surveillance Intervention Active (ASIA) study, 23 metabolic outcomes were compared over 6 months in patients on usual recommendations to those with these recommendations combined with SMBG. None of the subjects were taking insulin. The authors observed better quality of metabolic control in the SMBG group. The HbA1c level at baseline was the most important predicting factor for improvement of metabolic control. The same results were obtained from our study in relation to the baseline HbA1c level and effect of SMBG on metabolic outcome. In the ASIA study, however, no specific information was provided to the patients in order to incorporate SMBG findings into self-care behaviors. Meanwhile, patients in the SMBG group were asked to titrate their medication according to fasting plasma glucose.
These results are in contrast with those reported in the Diabetes Glycemic Education and Monitoring (DiGEM) study, which found no beneficial effect of SMBG on glycemic control in noninsulin-treated T2DM. 26 Considering the economic burden of SMBG and its effects on quality of life, the DiGEM trial group reported higher cost and lower quality of life in patients with noninsulin-treated T2DM. However, they mentioned that SMBG might be cost-effective in patients who adhere tightly to the treatment recommendations.
In our study, we included patients with high compliance. So, the improvement in glycemic control might have reflected the incorporation of SMBG findings into self-care and a meaningful lifestyle response to the data obtained from SMBG. Meanwhile, we observed a beneficial effect of SMBG on glycemic control in poorly controlled T2DM patients with higher HbA1c level at baseline. Some other studies also showed no significant difference on metabolic outcome using SMBG. 27, 28 Karter and colleagues 19 reported the impact of SMBG on the management of patients who were not treated with insulin. They claimed that SMBG with or without instruction might not improve glycemic control compared with usual care in well-controlled T2DM patients, similar to the results we reported in our study in the subgroup of patients with HbA1c less than 8%.
In the ESMON study, 29 noninsulin-treated newly diagnosed people with T2DM were randomized to SMBG and a control group in order to evaluate the efficacy of SMBG on glycemic control, body mass index (BMI), and psychological indices. SMBG had no beneficial effect on HbA1c after 1 year, and no significant differences in BMI were reported between the SMBG and control groups. Meanwhile, SMBG was associated with a slightly higher score on a depression subscale.
There are some possibilities to explain these controversial issues. One possibility is that nonstructured SMBG might not provide sufficient and valid information for the patients to act upon the results. In other words, random measurements do not provide adequate information for decision-making and this may lead to patient dissatisfaction and anxiety. 25 In a large epidemiological study, Karter and colleagues 19 reported a link between HbA1c and frequency of SMBG. Another explanation is the absence of clear instructions to incorporate finding into self-care practice. As a result, patients might not use the information to change their lifestyle. 30 Aikens and colleagues 31 reported that self-care behaviors improved diabetes outcomes. Other studies also showed that knowledge as well as behavior change are effective on patient lifestyle, which is important regarding diabetes control and cardiovascular outcomes. 32, 33 Using a simple SMBG tool that can be integrated easily into a comprehensive diabetes management approach was the most significant point of strength in our study. We showed that lifestyle adaptation is intuitively the right way to manage patients with diabetes. Verification of SMBG results by data download giving "hard" data was another point of strength. However, the most important limitation of our study was the small sample size.
Conclusion
This study showed effectiveness of structured SMBG on patient empowerment and better metabolic control in people with T2DM. This improvement results from more active participation of patients in self-care management, better compliance with treatment protocols, and smaller attrition rate compared to other interventions.
In our study, we showed that adherence to the structured SMBG enabled patients to interpret the results in relation to their level of activity and portion size, and motivated them to act upon the results in order to have a better metabolic outcome.
